Committee Correspondence
The Committee on Energy and Commerce
W.J. "Billy" Tauzin,  Chairman

Committee Leaders Question National Collegiate Athletic Association Regarding the Use of Ephedra-Containing Supplements

April 9, 2003

Dr. Myles Brand
President
National Collegiate Athletic Association
P.O. Box 6222
Indianapolis, IN 46206

Dear. Dr. Brand:

The recent death of 23-year old Baltimore Orioles pitcher Steve Bechler, whose use of an ephedra-containing supplement was a contributing factor in his tragic death, according to the Broward County Medical Examiner's Office, has raised questions about whether Federal action should be taken to address safety concerns related to ephedra-containing supplements. The Committee on Energy and Commerce has jurisdiction over matters relating to food and drugs, the regulation of commercial practices, including sports-related matters, and public health generally. Accordingly, we have initiated a comprehensive review of safety issues surrounding the use of ephedra-containing supplements.

In response to new studies providing additional evidence of safety concerns that may be associated with ephedra-containing supplements, the Department of Health and Human Services (HHS) recently announced several regulatory and enforcement actions intended to protect Americans from potentially serious risks of ephedra-containing supplements. HHS also issued a public statement cautioning the public about the use of ephedra-containing supplements, particularly in combination with strenuous exercise or other stimulants. Moreover, HHS is seeking expedited public comment on: (1) new evidence on health risks associated with ephedra to establish an up-to-date record as quickly as possible to support new restrictions on ephedra-containing products; (2) whether the currently available evidence and medical literature indicate a "significant or unreasonable risk of illness or injury" from dietary supplements containing ephedra; and (3) a new warning label on any ephedra supplements that continue to be marketed.

According to various media accounts, ephedra has been linked to numerous deaths and 1,400 reports of health-related problems, including strokes, heart attacks and seizures. A recent study published in the Annals of Internal Medicine that compared the safety of ephedra supplements to other herbal supplements concluded that the relative risk for an adverse reaction from ephedra supplements was more than 100-fold higher compared to any other herb. The study also notes that 64% of all adverse reactions to herbal supplements in the U.S. came from supplements containing ephedra, while ephedra-containing products represented only 0.82% of herbal product sales. The recently released results of a RAND Corporation study commissioned by the National Institutes of Health (NIH) provides additional evidence that ephedra-containing supplements may be associated with increased health risks, while finding only limited evidence of health benefits resulting from ephedra use.

In light of the potential adverse effects of ephedra-containing products, the National Football League ("NFL"), as well as the International Olympic Committee ("IOC") and the National Collegiate Athletic Association ("NCAA"), decided to ban the use of ephedra products among their athletes. It is our understanding that beginning in 1997 ephedrine was included in the NCAA's list of banned substances; however, it was not until August 2002 that the NCAA added ephedrine testing to its year-round drug testing program. The Committee is seeking additional information from the NCAA concerning its decision to ban the use of ephedra products among its players and its policies adopted to enforce the ban on ephedra use in professional football.

Due to recent press reports raising additional questions about the safety of ephedra products and the NCAA's decision to ban the use of ephedra products among its players, we are requesting that, pursuant to Rules X and XI of the U.S. House of Representatives, you provide the Committee with the information requested below by Wednesday, April 23, 2003.

  1. Explain the NCAA's policies and procedures regarding the use of ephedra products among collegiate athletes and include in your response whether the NCAA consulted with players, coaches and/or other individuals in determining these policies and procedures, and if so, identify all persons who were consulted on this matter. Provide a copy of all policies and procedures that relate to the use of ephedra by collegiate athletes.

  2. Explain when and why the NCAA decided to institute drug testing of collegiate athletes for ephedrine and provide all records that relate to your decision to institute testing among your players.

  3. From 1995 through the present, state whether the NCAA has procedures relating to reporting or tracking of adverse health events among collegiate athletes. If so, identify the entities to which these reports are made, the individual(s) responsible for retaining such information, and describe the specific procedures and whether they apply to adverse events relating to dietary supplements (including, but not limited to, ephedra products). Provide a copy of all procedures described in this question.

  4. Since the NCAA began testing collegiate athletes for ephedrine use, state how many athletes have been randomly tested for ephedrine use and, among those players tested, how many players have tested positive for ephedrine use.

  5. Identify who the NCAA consulted with concerning the decision to ban the use of ephedrine and/or the NCAA's decision to test its athletes for ephedrine. For each person(s), provide the name of the organization to which they are affiliated, the date(s) of any meetings, and provide all records that relate to the consultation.

  6. State whether any employee or agent of the NCAA has reviewed or requested a review of any scientific literature that concerns the health effects of dietary supplements (including, but not limited to, ephedra products) on athletes or other persons. If so, provide the following information:

  1. The name of author and title and date of literature;

  2. The identity of the person(s) within the NCAA (or person acting at its request) that reviewed the literature;

  3. The date when the literature was reviewed; and

  4. All records relating to such review.

  1. Prior to the ban on ephedra products, state whether the NCAA received or reviewed any health complaints or notification of adverse health events relating to ingestion of dietary supplements (including, but not limited to, ephedra products) by collegiate athletes. If so, provide the number of complaints, an identifier for each complainant, the date of each complaint, the person or entity to which each complaint was referred, and a description of the resolution of each complaint, including any action taken by NCAA or other entity in response.

  2. All records that relate to the NCAA's position on the banning and/or use of ephedra products and the testing for ephedrine in collegiate athletes.

Please note that, for purposes of responding to this request, the terms "records" and "relating" should be interpreted in accordance with the attachment to this letter. The term "you" or "your" means the National Collegiate Athletic Association or one or more of its divisions, subsidiaries or affiliates, or related entities.

If you have any questions, please contact Alan Slobodin, at (202) 225-2927, or Kelli Andrews, at (202) 226-2424, of the Committee Staff.

Sincerely,

 

W.J. "Billy" Tauzin
Chairman

Michael Bilirakis
Chairman
Subcommittee on Health 

Cliff Stearns
Chairman
Subcommittee on Commerce, Trade, and Consumer Protection

James C. Greenwood
Chairman
Subcommittee on Oversight & Investigations

ATTACHMENT

  1. The term "records" is to be construed in the broadest sense and shall mean any written or graphic material, however produced or reproduced, of any kind or description, consisting of the original and any non-identical copy (whether different from the original because of notes made on or attached to such copy or otherwise) and drafts and both sides thereof, whether printed or recorded electronically or magnetically or stored in any type of data bank, including, but not limited to, the following: correspondence, memoranda, records, summaries of personal conversations or interviews, minutes or records of meetings or conferences, opinions or reports of consultants, projections, statistical statements, drafts, contracts, agreements, purchase orders, invoices, confirmations, telegraphs, telexes, agendas, books, notes, pamphlets, periodicals, reports, studies, evaluations, opinions, logs, diaries, desk calendars, appointment books, tape recordings, video recordings, e-mails, voice mails, computer tapes, or other computer stored matter, magnetic tapes, microfilm, microfiche, punch cards, all other records kept by electronic, photographic, or mechanical means, charts, photographs, notebooks, drawings, plans, inter-office communications, intra-office and intra-departmental communications, transcripts, checks and canceled checks, bank statements, ledgers, books, records or statements of accounts, and papers and things similar to any of the foregoing, however denominated.

  2. The terms "relating," "relate," or "regarding" as to any given subject means anything that constitutes, contains, embodies, identifies, deals with, or is in any manner whatsoever pertinent to that subject, including but not limited to records concerning the preparation of other records.


Related Documents

Ephedra Investigation

Sports


The Committee on Energy and Commerce
2125 Rayburn House Office Building
Washington, DC 20515
(202) 225-2927
Feedback